Lexicon PHARMACEUTICALS, Inc. (LXRX) intrinsic value & 10-year financials
Lexicon PHARMACEUTICALS, Inc. (LXRX) has a Graham intrinsic value of $38.53 per share. At $1.52 on Oct 17, 2026, the stock trades 96% below that value. Over the last 10 fiscal years revenue grew 15.3% a year to $49.8M, with an average return on invested capital of -82.3%.
- Graham intrinsic value
- $38.53
- Share price (Oct 17, 2026)
- $1.52
- Price vs Graham value
- 96% below
- Market cap
- $551.8M
- Revenue (FY2025)
- $49.8M
- Revenue growth (10-yr CAGR)
- 15.3%
- ROIC (10-yr avg)
- -82.3%
- Free cash flow (FY2025)
- -$67.9M
LXRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $49.8M | -$50.3M | -$0.14 | -$67.9M | -98.2% | -31.7% |
| FY2024 | $6.0M | -$200.4M | -$0.63 | -$179.8M | -3284.7% | -109.6% |
| FY2023 | $1.1M | -$177.1M | -$0.80 | -$162.4M | -15473.0% | -136.5% |
| FY2022 | $0 | -$101.9M | -$0.62 | -$90.2M | — | -158.8% |
| FY2021 | $0 | -$87.8M | -$0.60 | -$88.2M | — | -213.9% |
| FY2020 | $23.4M | -$58.6M | -$0.53 | -$143.1M | -204.2% | -103.8% |
| FY2019 | $32.3M | $130.1M | $1.16 | $113.7M | 437.5% | 118.1% |
| FY2018 | $26.6M | -$120.5M | -$1.14 | -$148.7M | -388.5% | -64.4% |
| FY2017 | $15.9M | -$129.1M | -$1.17 | -$185.6M | -860.2% | -57.6% |
| FY2016 | $0 | -$141.4M | — | -$175.9M | — | -64.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LEXICON PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LEXICON PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -45.4% ROIC.
LEXICON PHARMACEUTICALS, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, LEXICON PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $38.53 per share.